Evidence generation increasingly depends on real-world data, but access delays, sparse populations, limited comparators, and privacy constraints can leave critical evidence questions unanswered. Synthetic data offers a way to reduce these barriers by creating statistically representative datasets that support faster analysis, testing, collaboration, and bias assessment. Its value, however, depends on rigorous validation, clear governance,…

Drug discovery is evolving rapidly, but successful AI adoption requires more than powerful models. It demands validated evidence, robust governance, and realistic expectations. AI empowers life sciences teams to accelerate drug discovery through evidence synthesis and expert human validation, delivering faster scientific insights while maintaining transparency, traceability, and regulatory-grade quality. Download Deploying AI in Drug…

Drug repurposing has the potential to deliver new therapies faster and at a fraction of the cost of traditional drug development. However, identifying meaningful opportunities remains difficult, with valuable signals often hidden across thousands of research publications. AI-powered literature reviews, combined with expert human validation, accelerate evidence synthesis while maintaining transparency, accuracy, and regulatory-grade quality.…

AI adoption in evidence synthesis often stalls when traceability, governance, and real-world validation requirements enter the picture. Most evaluations still focus on isolated models instead of the full systems used in regulated workflows. AI embeds human validation, workflow orchestration, auditability, and governance throughout the evidence-synthesis process, helping organizations build defensible, production-ready workflows. Download Rethinking…

AI adoption in life sciences keeps stalling at the same point when compliance, traceability, and validation requirements enter the room. Most pilots never make it to regulatory or payer decision-making. AI addresses exactly that gap by embedding governance, auditability, and human validation into every workflow, enabling HEOR, Market Access, and Medical Affairs teams to move…

Developing Global Value Dossiers (GVDs) is one of the most complex and time-consuming steps in the market access process. Medical Affairs, HEOR, and Regulatory teams must synthesize large volumes of clinical, economic, and real-world evidence while meeting the requirements of multiple HTA bodies across global markets. AI-powered GVD automation enables life sciences teams to accelerate…